E-LIB Suche - Ergebnisse für: Rózsa, Csilla

1

Efgartigimod demonstrates consistent improvements in patien..:

Siddiqi, Zaeem ; Rozsa, Csilla ; Saccá, Francesco...
Journal of the Neurological Sciences. 455 (2023) - p. 121094 , 2023

Link: https://doi.org/10.1016/..

2

Treatment of relapsing multiple sclerosis in Hungary – cons..:

Rajda, Cecilia ; Rózsa, Csilla ; Mike, Andrea...
Orphanet Journal of Rare Diseases. 18 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

3

Randomized Double-Blind Placebo-Controlled Trial of the Cor..:

Bril, Vera ; Szczudlik, Andrzej ; Vaitkus, Antanas...
Neurology. 100 (2023) 7 - p. , 2023

Link: https://doi.org/10.1212/..

4

The safety and efficacy of fingolimod: Real-world data from..:

Biernacki, Tamás ; Sandi, Dániel ; Füvesi, Judit...
PLOS ONE. 17 (2022) 4 - p. e0267346 , 2022

Link: https://doi.org/10.1371/..

5

Comparative Effectiveness and Cost-Effectiveness of Nataliz..:

Spelman, Timothy ; Herring, William L. ; Zhang, Yuanhui...
PharmacoEconomics. 40 (2021) 3 - p. 323-339 , 2021

Link: https://doi.org/10.1007/..

6

Population-based head-to-head comparison of the clinical ch..:

Viktoria, Papp ; Trones, Kim D.P. ; Magyari, Melinda...
Multiple Sclerosis and Related Disorders. 51 (2021) - p. 102879 , 2021

Link: https://doi.org/10.1016/..

7

Factors influencing daily treatment choices in multiple scl..:

Berger, Thomas ; Adamczyk-Sowa, Monika ; Csépány, Tünde...
Therapeutic Advances in Neurological Disorders. 13 (2020) - p. 175628642097522 , 2020

Link: https://doi.org/10.1177/..

8

Contributing factors to health‐related quality of life in m..:

Biernacki, Tamás ; Sandi, Dániel ; Kincses, Zsigmond Tamás...
Brain and Behavior. 9 (2019) 12 - p. , 2019

Link: https://doi.org/10.1002/..

9

Management of multiple sclerosis patients in central Europe..:

Berger, Thomas ; Adamczyk-Sowa, Monika ; Csépány, Tünde...
Therapeutic Advances in Neurological Disorders. 11 (2018) - p. 175628641875918 , 2018

Link: https://doi.org/10.1177/..

10

A comparative effectiveness analysis applying a 3-way prope..:

Spelman, Timothy ; Havrdova, Eva ; Horakova, Dana...
Neurology. 90 (2018) 15_supplement - p. , 2018

Link: https://doi.org/10.1212/..

11

Safety and efficacy in patients receiving natalizumab thera..:

Csepany, Tunde ; Lovas, Gabor ; Bencsik, Krisztina...
Neurology. 88 (2017) 16_supplement - p. , 2017

Link: https://doi.org/10.1212/..

12

Prevalence of cognitive impairment among Hungarian patients..:

Sandi, Dániel ; Biernacki, Tamás ; Szekeres, Dóra...
Multiple Sclerosis and Related Disorders. 17 (2017) - p. 57-62 , 2017

Link: https://doi.org/10.1016/..

13

Predictors of long‐term disability accrual in relapse‐onset..:

Jokubaitis, Vilija G. ; Spelman, Tim ; Kalincik, Tomas...
Annals of Neurology. 80 (2016) 1 - p. 89-100 , 2016

Link: https://doi.org/10.1002/..

14

The effects of fatigue, depression and the level of disabil..:

Fricska-Nagy, Zsanett ; Füvesi, Judit ; Rózsa, Csilla...
Multiple Sclerosis and Related Disorders. 7 (2016) - p. 26-32 , 2016

Link: https://doi.org/10.1016/..

15

Switch to natalizumab versus fingolimod in active relapsing..:

Kalincik, Tomas ; Horakova, Dana ; Spelman, Tim...
Annals of Neurology. 77 (2015) 3 - p. 425-435 , 2015

Link: https://doi.org/10.1002/..